Navigation Links
Hemispherx Presents Evidence of Ampligen Synergies with Existing,Antivirals at International Avian Influenza Conference

peutic that exhibits antiviral activity by different mechanisms than either Tamiflu or Relenza; it has completed Phase III clinical testing for another disorder, Chronic Fatigue Syndrome (CFS).

"With so few lines of defense currently available against avian influenza, it is crucial to discover lasting ways to extend and enhance the effectiveness of existing therapies, as has been done historically with other devastating viral diseases including HIV/AIDS and hepatitis," commented Dr. William Carter, Chairman and Chief Executive Officer of Hemispherx. "We are pleased to share the results of our studies of combination therapies involving Ampligen(R) and look forward to accelerating this development program under the "animal rule" for fast tracking experimental therapeutics for life threatening disorders." Under the "animal rule," extensive clinical studies can be replaced by animal model studies to evaluate efficacy under certain circumstances.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) and the experimental therapeutics Ampligen(R) and Oragens(R). Alferon N Injection(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information cont
'"/>




Page: 1 2 3

Related medicine technology :

1. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:11/21/2014)... 20, 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" ... appointments: Todd Martensen has ... created role of Chief Commercial Officer, to oversee KLOX,s ... photoconverter gel for the treatment of chronic and other ... recently approved in Europe . Mr. ...
(Date:11/21/2014)... Michael DeMarco (42) erinnert sich ... Februar 2014 zugetragen hat. Seine Tochter Aly Demarco (13) ... Video - http://youtu.be/5cVoMCe0uiE „Man ... Training zu machen", erzählt Michael DeMarco . „Meine ... begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, ...
(Date:11/21/2014)... 2014   Coqui RadioPharmaceuticals Corp. , a medical ... producer of Molybdenum-99 (Mo-99), is proud to announce it ... to design its Medical Isotope Production Facility (MIPF) in ... parent isotope of Technetium-99, which is used in 80 ... passed legislation making it a national priority to produce ...
Breaking Medicine Technology:KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2011  Quest Diagnostics Incorporated (NYSE: DGX ), ... services, today announced that its Board of Directors has ... effective immediately. Including Mr. Ring, the Board has nine ... of C. R. Bard, Inc., a leading multinational developer, ...
... Dec. 7, 2011 Aoxing Pharmaceutical (NYSE Amex: ... pharmaceutical company focusing on research, development, manufacturing and ... today announced that its operating subsidiary in China, ... three-way financing agreement with Shijiazhuang Construction Investment Group ...
Cached Medicine Technology:Quest Diagnostics Adds Timothy M. Ring to Board of Directors 2Aoxing Pharmaceutical Company Announces $3.2 Million Financing 2Aoxing Pharmaceutical Company Announces $3.2 Million Financing 3
(Date:11/22/2014)... A petition seeking a ban on ... in minimally-invasive hysterectomies and fibroid removal surgeries has gained ... October, Bernstein Liebhard LLP reports. According to Change.org, ... 21st, 2014. That represents an increase of 456 signatures ... to the campaign.* , The campaign to ban uterine ...
(Date:11/22/2014)... November 22, 2014 This month has been ... because it has received many positive reviews from some renowned ... of its products by launching a new selection of wonderful ... global customers can enjoy free shipping and up to an ... Stylish ladies can always find the most suitable dress at ...
(Date:11/22/2014)... Sandbridge Capital, a private equity ... consumer brand sector, acquired a minority stake in ... to help fund BackJoy’s global growth and accelerate ... proprietary apparel and footwear lines. Sandbridge Capital Managing ... Directors. , BackJoy is a high-growth health and ...
(Date:11/22/2014)... November 22, 2014 A Xarelto lawsuit has ... who is seeking $10 million in damages from the makers ... According to the lawsuit, the woman began using Xarelto in ... alleges in her lawsuit she suffered life-threatening bleeding in July ... injuries, pain, suffering and emotional distress. The lawsuit purports that ...
(Date:11/22/2014)... Nov. 21, 2014 (HealthDay News) -- The widely used ... death and hospitalization among patients who have the heart ... failure, a new study finds. Atrial fibrillation is ... linked to a rise in risk for stroke among ... a century to help treat irregular heartbeat, the authors ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3
... -- The use of long-distance video and data hookups to ... provides the same level of care as having everyone in ... at the Canadian Stroke Congress. The study found that ... Telestroke received an important stroke drug, tPA, at the same ...
... Gordon HealthDay Reporter , MONDAY, Oct. 3 (HealthDay ... sexually transmitted human papillomavirus (HPV) rose dramatically over two decades, ... these types of tumors might become the leading form of ... 1984 and 1989, just 16.3 percent of oral cancer samples ...
... , MONDAY, Oct. 3 (HealthDay News) -- In Utah, ... rate similar to those suspected of adult homicide, and they ... abuse homicide offenders are those who have failed to care ... ranks as one of the top five causes of childhood ...
... Sinai School of Medicine have found that $6.7 billion was ... medications in primary care, with 86 percent of that cost ... cholesterol. The findings are published in a research letter in ... Internal Medicine , one of the JAMA/Archives journals. ...
... cancer patients are given the choice, they are significantly more ... quality of life six months after treatment, compared to a ... scientific session, October 5, 2011, at the 53rd Annual Meeting ... finding challenges the perception that older cancer patients do not ...
... TORONTO, Ont., Oct. 3, 2011Studies that examined the possible link ... it,s impossible to reach a firm conclusion about the controversial ... found the blockages known as chronic cerebrospinal venous insufficiency, or ... than those who do not. But a team of ...
Cached Medicine News:Health News:Telestroke the next best thing 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 3Health News:Conviction Rates Similar for Suspects of Child, Adult Murder in Utah 2Health News:New research shows $6.7 billion spent on unnecessary tests and treatments in one year 2Health News:Cancer patients in their 60s are tech-savvy 2Health News:Researchers review studies on CCSVI-MS link 2
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: